ArticleOncoimmunology2021

Low-dose CDK4/6 inhibitors induce presentation of pathway specific MHC ligands as potential targets for cancer immunotherapy.

Angel Charles et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.